SIRT1 and hydrops fetalis: As metformin activates AMPK but not primarily SIRT1, gluconeogenesis and ketogenesis are inhibited among metformin users, in addition to reducing haematocrit and increasing uric acid levels; these are directly opposite to the effects of SGLT2i, and possibly attenuating SGLT2i-associated benefits on HF [29].